EP1697545B1 - Multiplex nucleic acid analysis of HPV genotypes - Google Patents
Multiplex nucleic acid analysis of HPV genotypes Download PDFInfo
- Publication number
- EP1697545B1 EP1697545B1 EP04815560A EP04815560A EP1697545B1 EP 1697545 B1 EP1697545 B1 EP 1697545B1 EP 04815560 A EP04815560 A EP 04815560A EP 04815560 A EP04815560 A EP 04815560A EP 1697545 B1 EP1697545 B1 EP 1697545B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- extension
- primers
- misc
- feature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
Abstract
Description
- The field of the invention is genetic diagnostics, and especially as it relates to multiplex analysis of a single sample.
- Despite recent advances in molecular diagnostics, numerous difficulties still remain. Among other problems, analysis of multiple potential genetic changes in a sample suspected to include a virus or oncogene frequently lead to false positive results, or fail to identify all potential changes as the number of such changes increases. Similar difficulties arise where one or more organisms are subject to genotyping or other genetic analysis.
- For example, human papillomavirus (HPV) is now considered a major cause of cervical cancer, killing more than 200,000 women around the world each year. The HPV virus is relatively common and more than 100 distinct types of HPV have been identified, some of which are considered "high-risk" for the development of cancer. Detection of such high-risk types of HPV has significant impact on diagnosis, prevention, treatment and management of cervical cancer in HPV-infected women.
- To date, most molecular methods for HPV detection and typing rely on hybridization technologies, including southern blot, dot blot, line blot, and in situ hybridization. For example, HybridCapture II from Digene is a nucleic acid hybridization microplate assay based on chemiluminescence for the qualitative detection, and differentiating low-risk from high-risk groups. Other commercially available tests employ similar methods and may detect the presence of various types of HPV in a patient sample. However, known HPV typing methods based on hybridization often lack specificity due to cross-hybridization. Cross-hybridization may result in a false positive signal due to closely related types of HPV (e.g., where a target DNA has only a single or few mismatches to the probes being used). Thus, the accuracy of the test results may be compromised with samples containing multiple viral types with closely related sequences.
- To overcome problems associated with cross-hybridization, a number of approaches have been taken. Typically, most of the improvements focus on exact control of the stringency conditions. For example, the specificity of hybridization can be controlled by temperature. However, temperature-specific hybridization may lead to false positive results if probes have a high degree of sequence similarity.
- Other efforts included the use of peptide nucleic acids (PNA), a universal base stretch, or modified bases (e.g., super G and C) to alter or otherwise affect hybridization/melting temperature of duplexes. Still further known methods involve use of conformationally locked DNA (e.g., to increase duplex stability), etc. While most of such approaches have provided at least some advantages, various problems nevertheless remain. Among other things, currently known approaches tend to fail to provide a significant difference between the melting and/or hybridization temperature of a perfectly matched hybrid and a single base mismatched hybrid.
- Fan, J-B et al., in Genome Research, Cold Spring Harbor Laboratory Press, Woodbury, NY, US, vol. 10, no. 6, 2000, p. 853-860, describes a parallel genotyping of human SNPs using generic high-density oligonucleotide tag arrays. First, marker-specific primers are used in PCR amplifications of genomic regions containing SSNPs. Second, the amplification products are used as templates in single base extension (SBE) reactions using chimeric primers.
- Hirschhorn, J. et al., in Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington D.C.,US, vol. 97, no. 22, 24 October 2000, describes a method for parallel genotyping SNPs by single base extension (SBE) using specific bi-functional primers.
-
WO 02/103050 A2 - Therefore, while numerous methods for nucleic acid based testing of HPV and other pathogens are known in the art, all or almost all of them suffer from various problems, which are even more aggravated, where such analysis is performed in a multiplex environment (e.g., a biochip). Consequently, there is still a need to provide improved methods and compositions for molecular diagnostics.
- The present invention is directed to genetic diagnostics in which specificity is substantially improved by using a combination of selected multiplex amplification primers and selected multiplex extension primers, wherein the sequences of the primers are designed to maximize hybridization specificity and extension selectivity in a multiplex reaction.
- The present invention relates to a multiplex diagnostic kit as defined in claims 1 and 7. The invention also relates to a synthetic nucleic acid for use as a primer as set out in claim 14. The multiplex diagnostic kit is based on a plurality of amplification primer pairs, and a plurality of extension primers, wherein each of the plurality of amplification primer pairs has a sequence such that (a) a plurality of amplicons produced from a target nucleic acid using the plurality of amplification primer pairs, respectively, includes a sequence difference (mutated position) in a target nucleic acid, (b) the plurality of amplicons is produced in a PCR reaction using the same amplification profile, and wherein each of the plurality of extension primers has a sequence such that (c) each of the plurality of extension primers specifically hybridizes to each of the plurality of amplicons at the same extension temperature, respectively, and selective primer extension for each of the plurality of extension primers is achieved at the same extension profile. Amplification primers and extension primers are those described in SEQ ID: 1 to 72.
- Particularly preferred kits further include a biochip to which are coupled in a plurality of distinct positions a plurality of distinct capture probes, respectively, and wherein each of the plurality of capture probes hybridizes with a portion of each of the extension primers, respectively. Most preferably, each of the plurality of the distinct capture probes has a unique sequence distinct from the target nucleic acid. Additionally, contemplated kits can include DNA-dependent DNA polymerase (e.g. thermostable, or specifically modified and/or isolated for primer extension), and/or an instruction (e.g., to perform the PCR reaction and primer extension in a single tube).
- The multiplex diagnostic kit includes at least two forward amplification primers having a sequence according to SEQ ID NO: 1 to 24, at least two backward amplification primers having a sequence according to SEQ ID NO: 25-48 and at least two extension primers having a sequence according to SEQ ID NO: 49-72. Such kits can further include an instruction to perform a multiplex PCR using the at least two forward amplification primers and the at least two backward amplification primers using the same amplification profile, and optionally an instruction to perform a primer extension reaction using the at least two extension primers at the same extension profile (typically in a single test tube).
- Additionally, or alternatively, a biochip is included in the test kit to which are coupled in a plurality of distinct positions a plurality of distinct capture probes, respectively, and wherein each of the plurality of capture probes hybridizes with a portion of each of the extension primers, respectively. Most preferably, each of the plurality of the distinct capture probes has a unique sequence distinct from a target nucleic acid to which the amplification primers bind. Where desired, contemplated kits may also include a reagent and/or an enzyme.
- In an other contemplated aspect of the inventive subject matter, a synthetic nucleic acid has less than forty nucleotides and comprises an HPV recognition sequence selected from the group consisting of SEQ ID NOs: 1 to 3 and 5 to 24 wherein no more than two nucleotides in the HPV recognition sequence are replaced by A, G, C, or T.
- Various objects, features, aspects and advantages of the present invention will become more apparent from the following detailed description of preferred embodiments of the invention.
- The inventors have unexpectedly discovered that a plurality of potential variants of a single gene can be identified in a single sample using a multiplex test in which amplification primers are used to specifically amplify a target sequence in that gene, wherein the amplicon includes at least one of the potential variants, and wherein extension primers are used to form an extension product that is specific to a variant of the gene.
- It should be especially noted that the specificity in such tests is substantially increased over conventional methods by the manner of primer selection. Specifically, the amplification primers are selected to have a sequence such that (a) a plurality of amplicons produced from a target nucleic acid using the amplification primers include sequence difference in a target nucleic acid, and (b) the plurality of amplicons is produced in a PCR reaction using the same amplification profile. In the same test, the extension primers are selected to have a sequence such that (c) the extension primers specifically hybridize to the corresponding amplicons at the same extension temperature (preferably such that the 3'-end of each of the extension primers corresponds to a complementary position of the mutated position), and (d) selective primer extension for each of the extension primers is achieved at the same extension temperature.
- Most preferably, the 5'-end of the extension primers further includes a tag (zipcode sequence) that is substantially not (typically less than 70%, and most typically less than 50%) complementary to the sequence of the amplicons and/or the sequence of the target gene, wherein the zipcode sequence is employed to hybridize with a capture probe (preferably on a biochip in a predetermined position). While not limiting to the inventive subject matter, the zipcode has typically a length between about two and twenty, more preferably between five and fifteen, and most preferably between eight and twelve nucleotides, wherein the tags of each of the extension primers are distinct (i.e., have a unique sequence), and wherein the zipcodes (and with that the distinct capture probes) have a unique sequence distinct from the target nucleic acid.
- With respect to the particular sequences of the amplification primers and the extension primers, it should be recognized that all sequences are deemed suitable and that the specific sequences will predominantly depend on the particular nature of the target nucleic acid and type of sequence difference that is to be detected. For example, suitable target nucleic acids include native and recombinant DNA (e.g., linear, circular, etc.), RNA (e.g., snRNA, hnRNA, mRNA, etc.), synthetic nucleic acids (e.g., phosphorothioates, PNA, etc.), all of which may be present in, or isolated from a biological source (e.g., biopsy, cell culture, swab, filtrate, plant material, etc.), a non-biological source (e.g., food, soil, water, oil, etc.), or may be entirely synthetic (e.g., on solid phase). Thus, it should be recognized that the length of contemplated target nucleic acids may vary considerably, and is typically between about 50 nucleotides to the length of an entire genome, chromosome, vector, chromosomal fragment, or transcript. Most preferably, the target nucleic acid is a viral or bacterial genome, or a nucleic acid comprising an oncogene, tumor suppressor gene, or other gene that is associated with a predisposition or presence of a disease. In the example, below, a particularly preferred target DNA is a viral DNA, and especially HPV DNA.
- It is generally preferred that the amplification primers have a length of between about 12 to 50 nucleotides, and more preferably between about 16 to 30 nucleotides, wherein the amplification primers may additionally (or optionally) include one or more nucleotides that provide one or more desirable properties. For example, contemplated amplification primers may include one or more nucleotides that render the primer (and/or amplicon) quantifiable and typical examples include radiolabeled nucleotides, fluorescence-labeled nucleotides, etc. In another example, contemplated amplification primers may also include one or more nucleotides that will facilitate specific isolation of the primer and/or amplicon (e.g., biotinylated nucleotide). Thus, amplicons generated by contemplated methods may be quantified to normalize a test result, especially where the test result provides a quantitative measure. Amplicons generated by contemplated tests will typically have a length of between about 50 to several thousand nucleotides.
- Similarly, preferred extension primers can have a length of between about 12 to 50 nucleotides, and more preferably between about 16 to 30 nucleotides, wherein the extension primers may additionally (or optionally) include one or more nucleotides that provide for one or more desirable properties. For example, particularly contemplated extension primers can include several additional nucleotides that allow specific hybridization of the additional nucleotides to a capture probe. Most preferably, the additional nucleotides have a sequence that is distinct from the sequence of the target nucleic acid (and even more typically of the amplicon). Therefore, capture of the extension product is independent of the target sequence, which further increases selectivity of the test. For example, various SNP-specific tests known in the art use solid-phase or otherwise immobilized extension primers, which tend to produce false positive results where the sequence difference among various mutant sequences allows cross-hybridization. Of course, it should be recognized that the sequence of the extension primer is selected from a sequence available in the amplicon.
- Depending on the particular target nucleic acid, contemplated amplification and/or extension primers can also include modified nucleotides and/or have one or more ambiguous positions (i.e., a position in which different nucleotides are present among otherwise identical primers). Ambiguous positions are denoted using the IUPAC nomenclature (R is A or G, Y is C or T, S is C or G, W is A or T, K is G or T, M is A or C, B is C or G or T, D is A or G or T, H is A or C or T, V is A or C or G, and N is A or C or G or T). Therefore, contemplated amplification and/or extension primers may have a single defined Tm at a particular solvent and temperature, or several distinct Tm.
- However, it should be recognized that the amplification primers are chosen such that a multiplex PCR using the amplification primers can be performed using a single amplification profile (wherein the term "amplification profile" refers to a specific combination of denature temperature and time, anneal temperature and time, and polymerization temperature and time), and that all amplicons produced from the multiplex PCR can be used for a primer extension reaction using the extension primers at a single extension temperature (wherein the term "extension temperature" refers to a specific combination of hybridization temperature and time and polymerization temperature and time). Preferred extension products are typically in the range of about 50 to several thousand bases, and it is especially preferred that the extension product includes one or more detectable (and more preferably quantifiable) label. For example, the extension reaction may be performed using one or more directly or indirectly labeled nucleotides, including nucleotides that carry a fluorescent, luminescent, or radioactive label (wherein the molar fraction of labeled nucleotide may be adjusted as appropriate), and/or nucleotides that carry an affinity marker (e.g., biotin, digitoxin) that binds a labeled compound or compound that can otherwise be detected and/or quantified.
- It is generally preferred that the extension primer has a sequence and is positioned such that proper hybridization of the extension primer (and especially correct hybridization of the terminal three 3' bases, more preferably terminal two 3' bases, and most preferably terminal 3' base) with the target nucleic acid will result in a detectable extension event. Typically the detectable event is a DNA polymerase-dependent DNA synthesis, wherein at least one of the nucleotides is labeled. Alternatively, the detectable event may also be a DNA ligation using a labeled fragment that abuts with it's 5'-end the 3'-end of the extension primer. With respect to the type of sequence difference that can be detected using contemplated methods, it should be recognized that all known sequence differences are suitable so long as information is available that allows design of the amplification primers and the extension primers. Thus, contemplated differences include deletions, insertions, translocations, and substitutions (e.g., transversion or transition). Furthermore, it should be noted that contemplated sequence differences also include sequence differences found in distinct viral genotypes. Thus, the nucleotide differences between or among various genotypes of a viral species are also considered mutations herein.
- Detection is preferably carried out on a biochip or other carrier onto which are immobilized in predetermined positions a plurality of capture probes that hybridize with at least a portion of the extension primer and/or extension product. Therefore, contemplated diagnostic kits can also include (next to contemplated amplification primers and/or extension primers) a biochip to which are coupled in a plurality of distinct positions a plurality of distinct capture probes, respectively, and wherein each of the plurality of capture probes hybridizes with at least a portion of each of the extension primers, respectively. In still further preferred aspects, contemplated capture probes may also include a fluorescent label, wherein the emission of the label is most preferably at a wavelength different from the detection wavelength of the extension product (e.g., Cy5 for the capture probe and Cy3 for the extension product). Among other advantages, such configurations allow normalization and/or calibration of a signal from the extension product. Additionally, or alternatively, suitable kits may include various enzymes (e.g., DNA-dependent DNA polymerase, ligase, etc.), buffers, and other reagents (e.g., labeled and unlabeled nucleotides).
- Table 1A shows the forward and backward amplification primers and corresponding extension primers for detection of genetic variants of HPV, wherein an extension primer in the same row as a forward and backward amplification primer will bind to the amplicon produced by the amplification primers. It should be noted that the primers in the Table 1A may include degenerate nucleotide positions. Therefore, primers with degenerate positions represent both individual sequences as well as mixtures of sequences defined by the ambiguity codes (e.g., ASA may represent AGA individually or ACA individually, but also a mixture of ACA and AGA together). Table 1B depicts a selection of certain primers of Table 1A with non-degenerate sequences.
TABLE 1A HPV SEQ ID. Upstream Primer SEQ ID. Downstream Primer SEQ ID. Extension Primer 6 A1 GCAACAACAGTTGAAGAAGAAAC B1 AGCTGTTGCACTTCTCTGATGTC C1 GAAGTGGACGGACAAGATTC 11 A2 GCACCTACAGTAGAAGAAGAAAC B2 AGGTCTTGTAGTTGTCTGATGTC C2 CAAGGTGGACAACACAGACG 16 A3 GTATATAGAGAKGGRAATCC B3 AATTGCTCATAACAGTRGAGRTCA C3 GCATGGAGATACACCTACATTG 18 A4 GTGTATAGAGACAGTATACCG B4 AATTGCTCGTGACATASAAGGTCA C4 GACAGGAACGACTCCAACGAC 26 A5 GTATATAGAGATAGGAGTCC B5 AATTGTTCGTARCASYGTAGGTCA C5 GAGACCAAGGCGCCAAACAG 31 A6 GTATATAGGGACGACACACC B6 AATTGCTCATAACAGTRGAGRTCA C6 CATGCGTGGAGAAACACCTACG 33 A7 GTATATAGAGAKGGRAATCC B7 AATTGCTCATARCAGTATAGGTCA C7 CGACGTAGAGAAACTGCACTG 35 A8 GTATATAGAGAAGGCCAGCC B8 AATTGCTCATARCAGTATAGGTCA C8 GACAGGTCGGTGTATGTCCT 39 A9 GTATATAGGGACGGGGAACC B9 AATTGCTCGTGACATASAAGGTCA C9 GACCGCAGACTAACACGAAGA 42 A10 TGGTATACAGTGGAGAAAGAAAC B10 CCCAAAAGCATCTGTTGCAG C10 TGACCAAGCCAAACAGGACA 43 A11 GCAGATACTGTAGAAGAAGAAAC B11 CAGTCTTCTAGCTTCTTGATGTC C11 GGACCAGCAAGTGAATCTAC 44 A12 GCAGTAACAGTGGAAGAAGAAAC B12 AGCGTATGTAGGTGATGGATGTC C12 CGCAAGACGTTACACAGCCT 45 A13 GTGTATAGAGACTGTATAGC B13 AATTGCTCGTARCACAMMAGGTCA C13 GAAAGACTTCGCAGACGTAGG 51 A14 GATTGTATATAGGGATAATAATCCAT B14 AATTGCTCRTRGCATTGCARGTCA C14 ACGTACACGACAACGTAACG 52 A15 GAATAGTATATAGAGACAATAATCC B15 AATTGCTCATAGCAGWRTAGGTCA C15 CTGTGACCCAAGTGTAACGTC 53 A16 GTGTATAGAGACGGGTATCC B16 AATTGCTCRTRGCATTGCARGTCA C16 GACCGGGTCGTGCCTGAC 56 A17 GTGTATAGGGATGATTTTCC B17 AATTGCTCATTGCAYTGTAGGTCA C17 GAGACAAACATCTAGAGAACC 58 A18 GTGTATAGAGATGGAAATCC B18 AATTGCTCATAGCAGWRTAGGTCA C18 GACAGGGCGCTGTGCAGTG 59 A19 GTGTATAGAGACTGTAGACC B19 AATTGCTCGTARCACAM MAGGTCA C19 CAAAGACAAGCGCGTAGTG 66 A20 AACTAGTATATAGAAACAATTGGC B20 AATTGCTCATTGCAYTGTAGGTCA C20 GACATACGAGTAGACAAGCTACAG 68 A21 GTAGTATATAGGGACGGGGTA B21 AATTGCTCGTGACATACAAGGTCG C21 GCAGACGCACACGGCAGG 69 A22 GAATAGTGTATAGAAATGATAGTGC B22 AATTGTTCGTARCASYGTAGGTCA C22 GGATGAAAAGCGACGGTTCC 73 A23 GTATTGTATATAGAAAGGATAAACC B23 CAATGACTCGTAACATGTAAGGTC C23 CGGTTTCATCAAATAGCAGAACA 82 A24 GTATATAGGACAATACGCC B24 AATTGCTCRTRGCATTGCARGTCA C24 GTGAAACCCAGGTGTAATAACG TABLE 1B HPV SEQ ID. Upstream Primer SEQ ID. Downstream Primer SEQ ID. Extension Primer 16 A25 GTATATAGAGATGGGAATCC B25 AATTGCTCATAACAGTAGAGATCA C3 GCATGGAGATACACCTACATTG 18 A4 GTGTATAGAGACAGTATACCG B26 AATTGCTCGTGACATAGAAGGTCA C4 GACAGGAACGACTCCAACGAC 26 A5 GTATATAGAGATAGGAGTCC B27 AATTGTTCGTAGCAGCGTAGGTCA C5 GAGACCAAGGCGCCAAACAG 31 A6 GTATATAGGGACGACACACC B28 AATTGCTCATAACAGTGGAGGTCA C6 CATGCGTGGAGAAACACCTACG 33 A26 GTATATAGAGAGGGAAATCC B29 AATTGCTCATAGCAGTATAGGTCA C7 CGACGTAGAGAAACTGCACTG 35 A8 GTATATAGAGAAGGCCAGCC B30 AATTGCTCATAACAGTATAGGTCA C8 GACAGGTCGGTGTATGTCCT 39 A9 GTATATAGGGACGGGGAACC B31 AATTGCTCGTGACATACAAGGTCA C9 GACCGCAGACTAACACGAAGA 45 A13 GTGTATAGAGACTGTATAGC B32 AATTGCTCGTAACACAACAGGTCA C13 GAAAGACTTCGCAGACGTAGG 51 A14 GATTGTATATAGGGATAATAATCCAT B33 AATTGCTCGTAGCATTGCAAGTCA C14 ACGTACACGACAACGTAACG 52 A15 GAATAGTATATAGAGACAATAATCC B34 AATTGCTCATAGCAGTGTAGGTCA C15 CTGTGACCCAAGTGTAACGTC 53 A16 GTGTATAGAGACGGGTATCC B35 AATTGCTCATGGCATTGCAGGTCA C16 GACCGGGTCGTGCCTGAC 56 A17 GTGTATAGGGATGATTTTCC B36 AATTGCTCATTGCACTGTAGGTCA C17 GAGACAAACATCTAGAGAACC 58 A18 GTGTATAGAGATGGAAATCC B37 AATTGCTCATAGCAGAATAGGTCA C18 GACAGGGCGCTGTGCAGTG 59 A19 GTGTATAGAGACTGTAGACC B38 AATTGCTCGTAGCACACAAGGTCA C19 CAAAGACAAGCGCGTAGTG 66 A20 AACTAGTATATAGAAACAATTGGC B39 AATTGCTCATTGCATTGTAGGTCA C20 GACATACGAGTAGACAAGCTACAG 69 A22 GAATAGTGTATAGAAATGATAGTGC B40 AATTGTTCGTAACACTGTAGGTCA C22 GGATGAAAAGCGACGGTTCC 82 A24 GTATATAGGACAATACGCC B41 AATTGCTCGTAGCATTGCAAGTCA C24 GTGAAACCCAGGTGTAATAACG - The amplification primers and extension primers correspond to the sequences provided in the sequence listing below, wherein SEQ ID: A1-A24 of Table 1A correspond to Sequence Numbers 1-24 of the sequence listing, respectively, wherein SEQ ID: B1-B24 of Table 1 correspond to Sequence Numbers 25-48 of the sequence listing, respectively, and wherein SEQ ID: C1-C24 of Table 1 correspond to Sequence Numbers 49-72 of the sequence listing, respectively. Furthermore, SEQ ID: A25-A26 of Table 1B correspond to Sequence Numbers 73-74 of the sequence listing, respectively, and SEQ ID: B25-B41 of Table 1B correspond to Sequence Numbers 75-91 of the sequence listing, respectively.
- The primers according to Tables 1A and 1B can further be modified to yield a synthetic nucleic acid having less than forty nucleotides and comprising an HPV recognition sequence selected from the group consisting of SEQ ID NOs: 1 to 3 and 5 to 24 wherein no more than two nucleotides in the HPV recognition sequence are replaced by A, G, C or T or other non-natural nucleotide.
- Especially contemplated kits will include at least two, more typically at least three to five, and most typically at least ten to twenty of the amplification primer pairs, and/or corresponding extension primers. In such kits, the PCR reaction and/or the primer extension is preferably performed in a single tube, which may be reflected in an instruction accompanying such kits. Alternatively, at least one of the PCR reaction and the primer extension can also be performed in an automated analyzer. Contemplated instructions may further provide information to perform the multiplex PCR using at least two forward amplification primers and at least two backward amplification primers using the same amplification profile, and/or information to perform the primer extension reaction using at least two extension primers at the same extension temperature.
- While not wishing to be bound by a particular hypothesis or theory, the inventors contemplate that the specificity of the tests according to the inventive subject matter is further improved by virtue of the fact that at least one of the hybridizations, and more preferably both hybridizations (i.e., for amplification and extension) is performed in solution rather than on a solid phase (which is thought to interfere with hybridization specificity). Furthermore, by the particular choice of primer selection, and especially by targeting distinguishing sequences among a plurality of otherwise similar or identical sequences, hybridization specificity of the amplification and/or extension primers is further increased.
- The following experiments were performed to provide exemplary guidance for a test to detect and genotype an HPV virus from a human sample. Here, HPV DNA was isolated from a pap smear using the Qiagen DNA isolation kit and an aliquot of the eluent was subjected to an off-line multiplex PCR using the forward and backward amplification primers with the SEQ ID A1-A24 and B1-B24, respectively. The PCR conditions were as follows:
- To 1 uL sample were added 18.75 uL HPV Amplification Solution, 0.25 uL (1.25 units) Platinum Taq Polymerase (Invitrogen) to a final volume of 20 uL. The HPV Amplification Solution was 21.34 mM Tris-HCL (pH 8.4), 53.35 mM KCL, 2.67 mM MgCl2, 33.34 uM dATP, 33.34 uM dGTP, 33.34 uM dTTP, 6.67 uM dCTP, and 26.68 to 80.03 nM for each of the forward and backward amplification primers.
- A 24-plex PCR using the primers of Table 1A was performed using the following amplification profile: Activation of Platinum Taq polymerase was performed by incubation at 94°C for 1 min followed by 40 cycles of 5 sec denaturation at 94°C, 30 sec annealing at 52°C and 40 sec elongation at 72°C. The contents of the multiplex PCR was then used in a subsequent primer extension using the extension oligos with the SEQ ID C1-C24 in a single well of a multi-well plate that was disposed in an automated analyzer as follows:
- The primer extension was performed in a 24 well plate in an automated analyzer using temperature controlled incubation of the extension mixture and reagents as follows:
- To the 20 uL volume from the multiplex PCR reaction were added 20 uL HPV Primer Extension Solution to a final volume of 40 uL. The HPV Primer Extension Solution was 20 mM Tris-HCL (pH 8.4), 50 mM KCL, 2.5 mM MgCl2, 31.25 uM dATP, 31.25 uM dGTP, 31.25 uM dTTP, 5 uM cy5dCTP, and 25 nM for each of the extension primers SEQ ID C1-C24. The extension profile was as follows: The PCR reaction was denatured at 94°C for 1 min followed by 40 cycles of 5 sec at 94°C and 10 sec at 51°C.
- The entire volume of the extension reaction was then transferred onto a biochip that included in predetermined position a plurality of capture nucleotides as described in our copending International applications
WO 03/050591 WO 02/057416 Table 2 INVENTIVE TEST (24 PLEX) REFERENCE TEST HR (45) HR neg neg neg neg HR (31, 66) HR, LR HR (16, 26, 33, 52, 82), LR (6) HR, LR HR (16) HR, LR HR (35, 58, 66) HR, LR HR (18, 53, 56), LR (42) HR, LR HR (39, 58) HR HR (35) HR neg neg HR (35, 52) HR HR (18) HR HR (18, 35) HR, LR -
- <110> Autogenomics
- <120> MULTIPLEXED HPV NUCLEIC ACID ANALYSIS WITH IMPROVED SPECIFICITY
- <130> 100788.0023PCT
- <150>
US 60/532681
<151> 2003-12-23 - <150>
US 60/556737
<151> 2004-03-26 - <160> 91
- <170> PatentIn version 3.2
- <210> 1
<211> 23
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence; IUPAC ambiguity code applies for all nucleotides other than A, C, G, and T. - <220>
<221> misc_feature
<222> (1)..(23)
<223> Forward Primer for HPV Type 6 - <400> 1
gcaacaacag ttgaagaaga aac 23 - <210> 2
<211> 23
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence; IUPAC ambiguity code applies for all nucleotides other than A, C, G, and T. - <220>
<221> misc_feature
<222> (1)..(23)
<223> Forward Primer for HPV Type 11 - <400> 2
gcacctacag tagaagaaga aac 23 - <210> 3
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Forward Primer for HPV Type 16 - <220>
<221> misc_feature
<222> (12)..(12)
<223> K is G or T - <220>
<221> misc_feature
<222> (15)..(15)
<223> R is A or G - <400> 3
gtatatagag akggraatcc 20 - <210> 4
<211> 21
<212> DNA
<213> Artificial
<220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(21)
<223> Forward Primer for HPV Type 18 - <400> 4
gtgtatagag acagtatacc g 21 - <210> 5
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Forward Primer for HPV Type 26 - <400> 5
gtatatagag ataggagtcc 20 - <210> 6
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Forward Primer for HPV Type 31 - <400> 6
gtatataggg acgacacacc 20 - <210> 7
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Forward Primer for HPV Type 33 - <220>
<221> misc_feature
<222> (12)..(12)
<223> K is G or T - <220>
<221> misc_feature
<222> (15)..(15)
<223> R is A or G - <400> 7
gtatatagag akggraatcc 20 - <210> 8
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Forward Primer for HPV Type 35 - <400> 8
gtatatagag aaggccagcc 20 - <210> 9
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1) .. (20)
<223> Forward Primer for HPV Type 39 - <400> 9
gtatataggg acggggaacc 20 - <210> 10
<211> 23
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(23)
<223> Forward Primer for HPV Type 42 - <400> 10
tggtatacag tggagaaaga aac 23 - <210> 11
<211> 23
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(23)
<223> Forward Primer for HPV Type 43 - <400> 11
gcagatactg tagaagaaga aac 23 - <210> 12
<211> 23
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(23)
<223> Forward Primer for HPV Type 44 - <400> 12
gcagtaacag tggaagaaga aac 23 - <210> 13
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Forward Primer for HPV Type 45 - <400> 13
gtgtatagag actgtatagc 20 - <210> 14
<211> 26
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(26)
<223> Forward Primer for HPV Type 51 - <400> 14
gattgtatat agggataata atccat 26 - <210> 15
<211> 25
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(25)
<223> Forward Primer for HPV Type 52 - <400> 15
gaatagtata tagagacaat aatcc 25 - <210> 16
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Forward Primer for HPV Type 53 - <400> 16
gtgtatagag acgggtatcc 20 - <210> 17
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Forward Primer for HPV Type 56 - <400> 17
gtgtataggg atgattttcc 20 - <210> 18
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Forward Primer for HPV Type 58 - <400> 18
gtgtatagag atggaaatcc 20 - <210> 19
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Forward Primer for HPV Type 59 - <400> 19
gtgtatagag actgtagacc 20 - <210> 20
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Forward Primer for HPV Type 66 - <400> 20
aactagtata tagaaacaat tggc 24 - <210> 21
<211> 21
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1) .. (21)
<223> Forward Primer for HPV Type 68 - <400> 21
gtagtatata gggacggggt a 21 - <210> 22
<211> 25
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(25)
<223> Forward Primer for HPV Type 69 - <400> 22
gaatagtgta tagaaatgat agtgc 25 - <210> 23
<211> 25
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(25)
<223> Forward Primer for HPV Type 73 - <400> 23
gtattgtata tagaaaggat aaacc 25 - <210> 24
<211> 19
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(19)
<223> Forward Primer for HPV Type 82 - <400> 24
gtatatagga caatacgcc 19 - <210> 25
<211> 23
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(23)
<223> Backward Primer for HPV Type 6 - <400> 25
agctgttgca cttctctgat gtc 23 - <210> 26
<211> 23
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(23)
<223> Backward Primer for HPV Type 11 - <400> 26
aggtcttgta gttgtctgat gtc 23 - <210> 27
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1) .. (24)
<223> Backward Primer for HPV Type 16 - <220>
<221> misc_feature
<222> (17)..(17)
<223> R is A or G - <220>
<221> misc_feature
<222> (21)..(21)
<223> R is A or G - <400> 27
aattgctcat aacagtrgag rtca 24 - <210> 28
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 18 - <220>
<221> misc_feature
<222> (17)..(17)
<223> S is C or G - <400> 28
aattgctcgt gacatasaag gtca 24 - <210> 29
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 26 - <220>
<221> misc_feature
<222> (12)..(12)
<223> R is A or G - <220>
<221> misc_feature
<222> (15)..(15)
<223> 5 is C or G - <220>
<221> misc_feature
<222> (16)..(16)
<223> Y is C or T - <400> 29
aattgttcgt arcasygtag gtca 24 - <210> 30
<211> 24
<212> DNA
<213> Artificial . - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 31 - <220>
<221> misc_feature
<222> (17)..(17)
<223> R is A or G - <220>
<221> misc_feature
<222> (21)..(21)
<223> R is A or G - <400> 30
aattgctcat aacagtrgag rtca 24 - <210> 31
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 33 - <220>
<221> misc_feature
<222> (12)..(12)
<223> R is A or G - <400> 31
aattgctcat arcagtatag gtca 24 - <210> 32
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 35 - <220>
<221> misc_feature
<222> (12)..(12)
<223> R is A or G - <400> 32
aattgctcat arcagtatag gtca 24 - <210> 33
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 39 - <220>
<221> misc_feature
<222> (17)..(17)
<223> S is C or G - <400> 33
aattgctcgt gacatasaag gtca 24 - <210> 34
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Backward Primer for HPV Type 42 - <400> 34
cccaaaagca tctgttgcag 20 - <210> 35
<211> 23
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(23)
<223> Backward Primer for HPV Type 43 - <400> 35
cagtcttcta gcttcttgat gtc 23 - <210> 36
<211> 23
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(23)
<223> Backward Primer for HPV Type 44 - <400> 36
agcgtatgta ggtgatggat gtc 23 - <210> 37
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 45 - <220>
<221> misc_feature
<222> (12)..(12)
<223> R is A or G - <220>
<221> misc_feature
<222> (17)..(18)
<223> M is A or C - <400> 37
aattgctcgt arcacammag gtca 24 - <210> 38
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 51 - <220>
<221> misc_feature
<222> (9)..(9)
<223> R is A or G - <220>
<221> misc_feature
<222> (11)..(11)
<223> R is A or G - <220>
<221> misc_feature
<222> (20)..(20)
<223> R is A or G - <400> 38
aattgctcrt rgcattgcar gtca 24 - <210> 39
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 52 - <220>
<221> misc_feature
<222> (16)..(16)
<223> W is A or T - <400> 39
aattgctcat agcagwrtag gtca 24 - <210> 40
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 53 - <220>
<221> misc_feature
<222> (9)..(9)
<223> R is A or G - <220>
<221> misc_feature
<222> (11)..(11)
<223> R is A or G - <220>
<221> misc_feature
<222> (20)..(20)
<223> R is A or G - <400> 40
aattgctcrt rgcattgcar gtca 24 - <210> 41
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 56 - <220>
<221> misc_feature
<222> (15)..(15)
<223> Y is C or T - <400> 41
aattgctcat tgcaytgtag gtca 24 - <210> 42
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 58 - <220>
<221> misc_feature
<222> (16)..(16)
<223> W is A or T - <220>
<221> misc_feature
<222> (17)..(17)
<223> R is A or G - <400> 42
aattgctcat agcagwrtag gtca 24 - <210> 43
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 59 - <220>
<221> misc_feature
<222> (12)..(12)
<223> R is A or G - <220>
<221> misc_feature
<222> (17)..(18)
<223> M is A or C - <400> 43
aattgctcgt arcacammag gtca 24 - <210> 44
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24) for HPV Type 66
<223> Backward Primer for HPV Type 66 - <220>
<221> misc_feature
<222> (15)..(15)
<223> Y is C or T - <400> 44
aattgctcat tgcaytgtag gtca 24 - <210> 45
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 68 - <400> 45
aattgctcat gacatacaag gtcg 24 - <210> 46
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 69 - <220>
<221> misc_feature
<222> (12)..(12)
<223> R is A or G - <220>
<221> misc_feature
<222> (15)..(15)
<223> 5 is C or G - <220>
<221> misc_feature
<222> (16)..(16)
<223> Y is C or T - <400> 46
aattgttcgt arcasygtag gtca 24 - <210> 47
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1) .. (24)
<223> Backward Primer for HPV Type 73 - <400> 47
caatgactcg taacatgtaa ggtc 24 - <210> 48
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 82 - <220>
<221> misc_feature
<222> (9)..(9)
<223> R is A or G - <220>
<221> misc_feature
<222> (11) .. (11)
<223> R is A or G - <220>
<221> misc_feature
<222> (20)..(20)
<223> R is A or G - <400> 48
aattgctcrt rgcattgcar gtca 24 - <210> 49
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1) .. (20)
<223> Extension Primer for HPV Type 6 - <400> 49
gaagtggacg gacaagattc 20 - <210> 50
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Extension Primer for HPV Type 11 - <400> 50
caaggtggac aacacagacg 20 - <210> 51
<211> 22
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(22)
<223> Extension Primer for HPV Type 16 - <400> 51
gcatggagat acacctacat tg 22 - <210> 52
<211> 21
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(21)
<223> Extension Primer for HPV Type 18 - <400> 52
gacaggaacg actccaacga c 21 - <210> 53
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Extension Primer for HPV Type 26 - <400> 53
gagaccaagg cgccaaacag 20 - <210> 54
<211> 22
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(22)
<223> Extension Primer for HPV Type 31 - <400> 54
catgcgtgga gaaacaccta cg 22 - <210> 55
<211> 21
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(21)
<223> Extension Primer for HPV Type 33 - <400> 55
cgacgtagag aaactgcact g 21 - <210> 56
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Extension Primer for HPV Type 35 - <400> 56
gacaggtcgg tgtatgtcct 20 - <210> 57
<211> 21
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(21)
<223> Extension Primer for HPV Type 39 - <400> 57
gaccgcagac taacacgaag a 21 - <210> 58
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Extension Primer for HPV Type 42 - <400> 58
tgaccaagcc aaacaggaca 20 - <210> 59
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Extension Primer for HPV Type 43 - <400> 59
ggaccagcaa gtgaatctac 20 - <210> 60
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Extension Primer for HPV Type 44 - <400> 60
cgcaagacgt tacacagcct 20 - <210> 61
<211> 21
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1) .. (21)
<223> Extension Primer for HPV Type 45 - <400> 61
gaaagacttc gcagacgtag g 21 - <210> 62
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Extension Primer for HPV Type 51 - <400> 62
acgtacacga caacgtaacg 20 - <210> 63
<211> 21
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(21)
<223> Extension Primer for HPV Type 52 - <400> 63
ctgtgaccca agtgtaacgt c 21 - <210> 64
<211> 18
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(18)
<223> Extension Primer for HPV Type 53 - <400> 64
gaccgggtcg tgcctgac 18 - <210> 65
<211> 21
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(21)
<223> Extension Primer for HPV Type 56 - <400> 65
gagacaaaca tctagagaac c 21 - <210> 66
<211> 19
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
- <221> misc_feature
<222> (1)..(19)
<223> Extension Primer for HPV Type 58 - <400> 66
gacagggcgc tgtgcagtg 19 - <210> 67
<211> 19
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(19)
<223> Extension Primer for HPV Type 59 - <400> 67
caaagacaag cgcgtagtg 19 - <210> 68
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Extension Primer for HPV Type 66 - <400> 68
gacatacgag tagacaagct acag 24 - <210> 69
<211> 18
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(18)
<223> Extension Primer for HPV Type 68 - <400> 69
gcagacgcac acggcagg 18 - <210> 70
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Extension Primer for HPV Type 69 - <400> 70
ggatgaaaag cgacggttcc 20 - <210> 71
<211> 23
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(23)
<223> Extension Primer for HPV Type 73 - <400> 71
cggtttcatc aaatagcaga aca 23 - <210> 72
<211> 22
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(22)
<223> Extension Primer for HPV Type 82 - <400> 72
gtgaaaccca ggtgtaataa cg 22 - <210> 73
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Forward primer for HPV Type 16 - <400> 73
gtatatagag atgggaatcc 20 - <210> 74
<211> 20
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(20)
<223> Forward Primer for HPV Type 33 - <400> 74
gtatatagag agggaaatcc 20 - <210> 75
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV Type 16 - <400> 75
aattgctcat aacagtagag atca 24 - <210> 76
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV Type 18 - <400> 76
aattgctcgt gacatagaag gtca 24 - <210> 77
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 26 - <400> 77
aattgttcgt agcagcgtag gtca 24 - <210> 78
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> backward primer for HPV type 31 - <400> 78
aattgctcat aacagtggag gtca 24 - <210> 79
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV type 33 - <400> 79
aattgctcat agcagtatag gtca 24 - <210> 80
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1) .. (24)
<223> Backward Primer for HPV Type 35 - <400> 80
aattgctcat aacagtatag gtca 24 - <210> 81
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV Type 39 - <400> 81
aattgctcgt gacatacaag gtca 24 - <210> 82
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward Primer for HPV Type 45 - <400> 82
aattgctcgt aacacaacag gtca 24 - <210> 83
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV type 51 - <400> 83
aattgctcgt agcattgcaa gtca 24 - <210> 84
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV type 52 - <400> 84
aattgctcat agcagtgtag gtca 24 - <210> 85
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV type 53 - <400> 85
aattgctcat ggcattgcag gtca 24 - <210> 86
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV type 56 - <400> 86
aattgctcat tgcactgtag gtca 24 - <210> 87
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV type 58 - <400> 87
aattgctcat agcagaatag gtca 24 - <210> 88
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV type 59 - <400> 88
aattgctcgt agcacacaag gtca 24 - <210> 89
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV type 66 - <400> 89
aattgctcat tgcattgtag gtca 24 - <210> 90
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV type 69 - <400> 90
aattgttcgt aacactgtag gtca 24 - <210> 91
<211> 24
<212> DNA
<213> Artificial - <220>
<223> Artificial sequence - <220>
<221> misc_feature
<222> (1)..(24)
<223> Backward primer for HPV type 82 - <400> 91
aattgctcgt agcattgcaa gtca 24
Claims (14)
- A multiplex diagnostic kit that allows concurrent detection of a plurality of HPV genotypes selected from 6, 11, 16, 18, 26, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73 and 82 comprising: a plurality of amplification primer pairs and a plurality of extension primers, wherein each of the plurality of amplification primer pairs has a sequence such that(a) a plurality of amplicons produced from a target nucleic acid using the plurality of amplification primer pairs, respectively, includes a mutated position in a target nucleic acid;(b) the plurality of amplicons is produced in a PCR reaction using the same amplification profile; and wherein each of the plurality of extension primers has a sequence such that(c) each of the plurality of extension primers specifically hybridizes to each of the plurality of amplicons at the same extension temperature, respectively, such that the 3'-end of each of the extension primers corresponds to a complementary position of the mutated position, respectively; and(d) selective primer extension for each of the plurality of extension primers is achieved at the same extension temperature;
which includes at least two amplification primer pairs including forward and backward amplification primers and at least two corresponding extension primers having the following sequences:SEQ ID:1, SEQ ID:25 and SEQ ID:49;SEQ ID:2, SEQ ID:26 and SEQ ID:50;SEQ ID:3, SEQ ID:27 and SEQ ID:51;SEQ ID:4, SEQ ID:28 and SEQ ID:52;SEQ ID:5, SEQ ID:29 and SEQ ID:53;SEQ ID:6, SEQ ID:30 and SEQ ID:54;SEQ ID:7, SEQ ID:31 and SEQ ID:55;SEQ ID:8, SEQ ID:32 and SEQ ID:56;SEQ ID:9, SEQ ID:33 and SEQ ID:57;SEQ ID:10, SEQ ID:34 and SEQ ID:58;SEQ ID:11, SEQ ID:35 and SEQ ID:59;SEQ ID:12, SEQ ID:36 and SEQ ID:60;SEQ ID:13, SEQ ID:37 and SEQ ID:61;SEQ ID:14, SEQ ID:38 and SEQ ID:62;SEQ ID:15, SEQ ID:39 and SEQ ID:63;SEQ ID:16, SEQ ID:40 and SEQ ID:64;SEQ ID:17, SEQ ID:41 and SEQ ID:65;SEQ ID:18, SEQ ID:42 and SEQ ID:66;SEQ ID:19, SEQ ID:43 and SEQ ID:67;SEQ ID:20, SEQ ID:44 and SEQ ID:68;SEQ ID:21, SEQ ID:45 and SEQ ID:69;SEQ ID:22, SEQ ID:46 and SEQ ID:70;SEQ ID:23, SEQ ID:47 and SEQ ID:71 andSEQ ID:24, SEQ ID:48 and SEQ ID:72whereby the primers with degenerate positions may be represented by the individual sequences or by a mixture of the sequences. - The multiplex diagnostic kit of claim 1 further comprising a biochip to which are coupled in a plurality of distinct positions a plurality of distinct capture probes, respectively, and wherein each of the plurality of capture probes hybridizes with a portion of each of the extension primers, respectively.
- The multiplex diagnostic kit of claim 2 wherein each of the plurality of the distinct capture probes has a unique sequence distinct from the target nucleic acid.
- The multiplex diagnostic kit of claim 1 further comprising a DNA-dependent DNA polymerase.
- The multiplex diagnostic kit of claim 1 wherein each of the extension primers further comprises a unique tag at the 5'-end of the extension primers to allow hybridization with a unique capture probe.
- The multiplex diagnostic kit of claim 1 further comprising an instruction to perform the PCR reaction and primer extension in a single tube.
- A multiplex diagnostic kit for concurrent detection of a plurality of HPV genotypes selected from 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 69 and 82, comprising at least two forward amplification primers and at least two backward amplification primers and corresponding extension primers having the following sequences:SEQ ID:73, SEQ ID:75 and SEQ ID:51;SEQ ID:4, SEQ ID:76 and SEQ ID:52;SEQ ID:5, SEQ ID:77 and SEQ ID:53;SEQ ID:6, SEQ ID:78 and SEQ ID:54;SEQ ID:74, SEQ ID:79 and SEQ ID:55;SEQ ID:8, SEQ ID:80 and SEQ ID:56;SEQ ID:9, SEQ ID:81 and SEQ ID:57;SEQ ID:13, SEQ ID:82 and SEQ ID:61;SEQ ID:14, SEQ ID:83 and SEQ ID:62;SEQ ID:15, SEQ ID:84 and SEQ ID:63;SEQ ID:16, SEQ ID:85 and SEQ ID:64;SEQ ID:17, SEQ ID:86 and SEQ ID:65;SEQ ID:18, SEQ ID:87 and SEQ ID:66;SEQ ID:19, SEQ ID:88 and SEQ ID:67;SEQ ID:20, SEQ ID:89 and SEQ ID:68;SEQ ID:22, SEQ ID:90 and SEQ ID:70 andSEQ ID:24, SEQ ID:91 and SEQ ID:72.
- The multiplex diagnostic kit of claim 7 further comprising an instruction to perform a multiplex PCR using the forward amplification primers and the backward amplification primers using the same amplification profile.
- The multiplex diagnostic kit of claim 8 further comprising an instruction to perform a primer extension reaction using the extension primers at the same extension temperature.
- The multiplex diagnostic kit of claim 9 further comprising an instruction to perform the multiplex PCR and the extension reaction in a single tube.
- The multiplex diagnostic kit of claim 7 further comprising a biochip to which are coupled in a plurality of distinct positions a plurality of distinct capture probes, respectively, and wherein each of the plurality of capture probes hybridizes with a portion of each of the extension primers, respectively.
- The multiplex diagnostic kit of claim 11 wherein each of the plurality of the distinct capture probes has a unique sequence distinct from a target nucleic acid to which the amplification primers bind.
- The multiplex diagnostic kit of claim 7 further comprising at least one of a reagent and an enzyme.
- A synthetic nucleic acid for use as a PCR primer in a multiplex test that has less than forty nucleotides and comprising an HPV recognition sequence selected from the group consisting of SEQ ID NOs: 1 to 3 and 5 to 24, wherein no more than two nucleotides in the HPV recognition sequence are replaced by A, G, C, or T.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08101207A EP1935992A3 (en) | 2003-12-23 | 2004-12-22 | Multiplexed nucleic acid analysis with high specificity for human papilloma virus |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53268103P | 2003-12-23 | 2003-12-23 | |
US55673704P | 2004-03-26 | 2004-03-26 | |
PCT/US2004/043499 WO2005064020A1 (en) | 2003-12-23 | 2004-12-22 | Multiplexed nucleic acid analysis with high specificity |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08101207A Division EP1935992A3 (en) | 2003-12-23 | 2004-12-22 | Multiplexed nucleic acid analysis with high specificity for human papilloma virus |
EP08101207.2 Division-Into | 2008-02-01 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1697545A1 EP1697545A1 (en) | 2006-09-06 |
EP1697545A4 EP1697545A4 (en) | 2007-08-15 |
EP1697545B1 true EP1697545B1 (en) | 2010-11-10 |
Family
ID=34743024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04815560A Not-in-force EP1697545B1 (en) | 2003-12-23 | 2004-12-22 | Multiplex nucleic acid analysis of HPV genotypes |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090233272A1 (en) |
EP (1) | EP1697545B1 (en) |
JP (1) | JP4628369B2 (en) |
AT (1) | ATE487799T1 (en) |
DE (1) | DE602004030036D1 (en) |
WO (1) | WO2005064020A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0601302D0 (en) * | 2006-01-23 | 2006-03-01 | Semikhodskii Andrei | Diagnostic methods and apparatus |
DK2209920T3 (en) * | 2007-11-01 | 2016-08-15 | Self-Screen B V | NEW CERVIX-HPV DETECTION PROCEDURE |
WO2009102369A2 (en) * | 2007-11-20 | 2009-08-20 | Autogenomics, Inc. | Multiplex assay for respiratory viruses |
EP2326732A4 (en) | 2008-08-26 | 2012-11-14 | Fluidigm Corp | Assay methods for increased throughput of samples and/or targets |
CN103952482A (en) | 2009-04-02 | 2014-07-30 | 弗卢伊蒂格姆公司 | Multi-primer amplification method for barcoding of target nucleic acids |
KR101350919B1 (en) * | 2011-03-14 | 2014-01-14 | (주)바이오니아 | Method of Identifying Nucleic Acid-Containing Materials |
SG10201605049QA (en) | 2011-05-20 | 2016-07-28 | Fluidigm Corp | Nucleic acid encoding reactions |
EP2852682B1 (en) | 2012-05-21 | 2017-10-04 | Fluidigm Corporation | Single-particle analysis of particle populations |
EP3390658B1 (en) | 2015-12-16 | 2022-08-03 | Standard BioTools Inc. | High-level multiplex amplification |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
AU694187B2 (en) * | 1994-02-07 | 1998-07-16 | Beckman Coulter, Inc. | Ligase/polymerase-mediated genetic bit analysis TM of single nucleotide polymorphisms and its use in genetic analysis |
WO2001092582A1 (en) * | 2000-06-01 | 2001-12-06 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ube3a gene |
EP1341934A4 (en) | 2000-12-12 | 2005-04-06 | Autogenomics Inc | Improved biochip |
CA2450164A1 (en) | 2001-06-14 | 2002-12-27 | University Of Wales College Of Medicine | Virus detection method, primers therefor and screening kit |
EP1481076A4 (en) * | 2001-07-12 | 2005-05-11 | Illumina Inc | Multiplex nucleic acid reactions |
US20050221283A1 (en) | 2001-12-11 | 2005-10-06 | Mahant Vijay K | Biochip |
-
2004
- 2004-12-22 AT AT04815560T patent/ATE487799T1/en not_active IP Right Cessation
- 2004-12-22 US US10/596,306 patent/US20090233272A1/en not_active Abandoned
- 2004-12-22 WO PCT/US2004/043499 patent/WO2005064020A1/en active Application Filing
- 2004-12-22 JP JP2006547430A patent/JP4628369B2/en not_active Expired - Fee Related
- 2004-12-22 DE DE602004030036T patent/DE602004030036D1/en active Active
- 2004-12-22 EP EP04815560A patent/EP1697545B1/en not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
JP2007515967A (en) | 2007-06-21 |
EP1697545A4 (en) | 2007-08-15 |
DE602004030036D1 (en) | 2010-12-23 |
ATE487799T1 (en) | 2010-11-15 |
EP1697545A1 (en) | 2006-09-06 |
WO2005064020B1 (en) | 2005-09-15 |
US20090233272A1 (en) | 2009-09-17 |
JP4628369B2 (en) | 2011-02-09 |
WO2005064020A1 (en) | 2005-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2949757B1 (en) | Method for multiplexing amplification reactions | |
US6268147B1 (en) | Nucleic acid analysis using sequence-targeted tandem hybridization | |
US9109261B2 (en) | Method and kit for identifying antibiotic-resistant microorganisms | |
JPH05244996A (en) | Detection of variant nucleic acid | |
US20030104372A1 (en) | Allele specific primer extension | |
CA2374406A1 (en) | Microarray-based analysis of polynucleotide sequence variations | |
WO2000026412A1 (en) | Nucleic acid analysis using sequence-targeted tandem hybridization | |
US20020127575A1 (en) | Partially double-stranded nucleic acids, methods of making, and use thereof | |
US9175339B2 (en) | Method for detection of target nucleic acid | |
Nilsson et al. | Making ends meet in genetic analysis using padlock probes | |
CA2704487A1 (en) | One-step target detection assay | |
WO2006097233A2 (en) | Determination of antibiotic resistance in staphylococcus aureus | |
EP1697545B1 (en) | Multiplex nucleic acid analysis of HPV genotypes | |
JP2006525809A5 (en) | ||
EP1620568B1 (en) | Allele-specific mutation detection assay | |
JP2004520838A (en) | Methods for detecting nucleic acid molecules | |
US20080026370A1 (en) | Method For Geno-And Pathotyping Pseudomonas Aeruginosa | |
Aydin et al. | New universal primers facilitate Pyrosequencing™ | |
EP1300473B1 (en) | Method of detecting nucleotide polymorphism | |
US20050095606A1 (en) | Partially double-stranded nucleic acids, methods of making, and use thereof | |
WO2002090516A2 (en) | Design of artificial genes for use as controls in gene expression analysis systems | |
EP1935992A2 (en) | Multiplexed nucleic acid analysis with high specificity for human papilloma virus | |
Hagiwara et al. | Development of an automated SNP analysis method using a paramagnetic beads handling robot | |
JP2002522047A (en) | Methods and compositions for regulating non-discriminatory hybridization to the limit | |
US20050079497A1 (en) | Multiple oligonucleotides per gene for use in gene arrays |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060621 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070713 |
|
17Q | First examination report despatched |
Effective date: 20080311 |
|
RTI1 | Title (correction) |
Free format text: MULTIPLEX NUCLEIC ACID ANALYSIS OF HPV GENOTYPES |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602004030036 Country of ref document: DE Date of ref document: 20101223 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20101110 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20101110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110310 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110310 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110210 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110221 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101231 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20110811 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20110210 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101231 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101222 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101231 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602004030036 Country of ref document: DE Effective date: 20110701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20111125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110210 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110511 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101110 |